Financial software provider SS&C Technologies (NASDAQ: SSNC) announced better-than-expected revenue in Q2 CY2026, with sales up 10.3% year on year to $1.70 billion. On the other hand, next quarter’s revenue guidance of $1.68 billion was less impressive, coming in 0.6% below analysts’ estimates. Its non-GAAP profit of $1.76 per share was 4.8% above analysts’ consensus estimates.
Is now the time to buy SSNC? Find out in our full research report (it’s free for active Edge members).
SS&C (SSNC) Q2 CY2026 Highlights:
- Revenue: $1.70 billion vs analyst estimates of $1.66 billion (10.3% year-on-year growth, 2.1% beat)
- Adjusted EPS: $1.76 vs analyst estimates of $1.68 (4.8% beat)
- Adjusted EBITDA: $672.3 million vs analyst estimates of $660.2 million (39.6% margin, 1.8% beat)
- The company slightly lifted its revenue guidance for the full year to $6.75 billion at the midpoint from $6.74 billion
- Management raised its full-year Adjusted EPS guidance to $7.09 at the midpoint, a 2.8% increase
- Operating Margin: 24.6%, up from 22.4% in the same quarter last year
- Billings: $1.67 billion at quarter end, up 9.7% year on year
- Market Capitalization: $16.12 billion
StockStory’s Take
SS&C’s second quarter results drew a strongly positive market reaction, as the company outperformed Wall Street’s revenue and non-GAAP profit expectations. Management attributed this to a combination of large technology license renewals, continued momentum in multiyear client contracts, and successful integration of recent acquisitions. CEO Bill Stone emphasized that organic revenue growth was boosted by the timing of major contract renewals, stating, “We did have a couple of big renewals in Q2, and that’s why organic revenue was up a couple of hundred extra basis points.” The quarter also benefited from robust demand in fund administration, with assets under administration up notably over the past two years.
Looking ahead, SS&C’s updated guidance reflects both continued investment in artificial intelligence (AI) capabilities and cautious assumptions around the timing of future contract renewals. Management expects ongoing adoption of Agentic AI, new digital investment solutions, and the scaling of products such as DomaniRx to support growth. However, CEO Bill Stone cautioned that “there are some renewals coming up as well, so we have opportunities to outperform…but we’re not going to pre-beat the drum.” The company plans to maintain disciplined capital allocation, emphasizing further integration of AI across its platforms while balancing margin improvement and reinvestment.
Key Insights from Management’s Remarks
Management pointed to large license renewals, rapid AI adoption, and strength in fund administration and healthcare technology as drivers of the quarter’s performance.
- License renewals timing: Organic revenue growth was notably higher due to the timing of large multiyear technology license renewals. CEO Bill Stone described the effect as “a little bit of the lumpiness of the business,” with several contracts contributing incremental revenue this quarter.
- AI-enabled product adoption: SS&C is deploying Agentic AI—AI agents capable of performing complex business processes—across its platforms. President Rahul Kanwar highlighted enterprise clients increasingly turning to SS&C for scalable automation, and cited a recent win with a global risk and reinsurance firm using the WorkHQ platform for Agentic automation.
- Healthcare platform scale: The launch of the Medicare GLP-1 Bridge Program, processed through SS&C’s DomaniRx platform, resulted in nearly 3 million claims in its first weeks. Management views this as validation of DomaniRx’s scalability and critical role in healthcare program delivery.
- Acquisition integration progress: The Curo and Calastone acquisitions, completed at the end of 2025, are performing ahead of expectations. Calastone, in particular, is expanding SS&C’s footprint in digital investment markets, with 431 new clients added and new solutions supporting tokenized fund transactions.
- Fund administration and market tailwinds: The fund administration segment, including GlobeOp, experienced strong growth. Management cited low redemption rates and significant increases in assets under administration as evidence of resilience and continued client confidence in SS&C’s offerings.
Drivers of Future Performance
Management expects revenue and margin growth to be driven by continued AI integration, new healthcare and digital investment solutions, and the timing of contract renewals.
- AI and automation expansion: SS&C is accelerating investment in AI and automation, especially Agentic AI, to improve operational efficiency and client offerings. Management believes this will support both revenue growth and margin expansion, as more clients seek to modernize operations without building in-house solutions.
- Healthcare and digital asset growth: The ongoing rollout of healthcare technology, including DomaniRx, and the expansion of digital investment capabilities through Calastone are expected to open new revenue streams. Management noted the potential for large-scale adoption if current pilot programs, such as the Medicare GLP-1 Bridge, are extended or replicated.
- Renewal and contract cycle impact: Future performance will be influenced by the timing of large multiyear contract renewals, which can create variability in organic growth rates. While the pipeline remains strong, management emphasized a disciplined approach and cautioned that results may fluctuate based on when renewals occur.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will focus on (1) the pace of adoption for Agentic AI and automation platforms across enterprise clients, (2) the scalability and renewal of healthcare initiatives such as the Medicare GLP-1 Bridge on DomaniRx, and (3) continued execution in integrating and expanding the Calastone and Curo acquisitions. Sustained growth in fund administration and further large contract renewals will also be key indicators to watch.
SS&C currently trades at $74.10, up from $66.95 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
Stocks That Trumped Tariffs
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
